SCHEMBL1159911

SCHEMBL1159911

O=C1C=CC(=O)N1CCOCCOCCOCCO

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 7/20 0.80
FAAH O00519 3/20 0.46
MAPK1 P28482 2/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
HSP90AA1 P07900 1/20 0.45
TLR9 Q9NR96 1/20 0.45
TP53 P04637 1/20 0.45
PKM P14618 1/20 0.45
HPGD P15428 1/20 0.45
XBP1 P17861 1/20 0.45
HTT P42858 1/20 0.45
RECQL P46063 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
GPR35 Q9HC97 1/20 0.45
GPR55 Q9Y2T6 1/20 0.45
MEN1 O00255 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16120722 1.00 MGLL (0.80) MGLLFAAHMAPK1ALDH1A1LMNA
SCHEMBL155061 1.00 MGLL (0.80) MGLLFAAHMAPK1ALDH1A1LMNA
SCHEMBL22311941 1.00 MGLL (0.80) MGLLFAAHMAPK1ALDH1A1LMNA
SCHEMBL22311911 1.00 MGLL (0.80) MGLLFAAHMAPK1ALDH1A1LMNA
SCHEMBL30831332 1.00 MGLL (0.80) MGLLFAAHMAPK1ALDH1A1LMNA
SCHEMBL31647549 1.00 MGLL (0.80) MGLLFAAHMAPK1ALDH1A1LMNA
SCHEMBL44460 0.98 MGLL (0.76) MGLLFAAHMAPK1ALDH1A1LMNA
SCHEMBL140275 0.89 MGLL (1.00) MGLLFAAHMAPK1ALDH1A1LMNA
SCHEMBL349749 0.89 MGLL (1.00) MGLLFAAHMAPK1ALDH1A1LMNA
SCHEMBL15082420 0.89 MGLL (1.00) MGLLFAAHMAPK1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120078903-A Ferritin nano-composite based on PROTAC and platinum drug synergistic effect and application thereof 中原纳米酶实验室 2025-06-03 CN claimed
CN-108289820-B Method for cosmetic treatment of keratin materials 莱雅公司 2021-07-13 CN claimed
EP-2140270-A1 METHOD OF MASS SPECTROMETRY Micromass UK Limited (GB) 2010-01-06 EP claimed
WO-2008125821-A1 METHOD OF MASS SPECTROMETRY MICROMASS UK LIMITED (GB) 2008-10-23 WO claimed
WO-2025134068-A1 ANTIBODY DRUG CONJUGATES TARGETING PROTEINOPATHIES, AND USES THEREOF AC IMMUNE SA (CH) 2025-06-26 WO disclosed
CN-120078903-A Ferritin nano-composite based on PROTAC and platinum drug synergistic effect and application thereof 中原纳米酶实验室 2025-06-03 CN disclosed
CN-119925628-A Albumin fixed-point modified lipid nanoparticle and preparation and application thereof 苏州大学 2025-05-06 CN disclosed
CN-108822267-B preparation and application of pH-responsive protein macromolecule amphiphile 清华大学 2022-12-16 CN disclosed
CN-108289820-B Method for cosmetic treatment of keratin materials 莱雅公司 2021-07-13 CN disclosed
CN-108822267-A preparation and application of pH-responsive protein macromolecule amphiphile 清华大学 2018-11-16 CN disclosed
EP-3337816-A1 ALBUMIN VARIANTS AND CONJUGATES Albumedix A/S (DK) 2018-06-27 EP disclosed
US-20170320965-A1 PAN-REACTIVE ANTIBODIES TO DUOCARMYCINS SYNTHON BIOPHARMACEUTICALS B.V. (NL) 2017-11-09 US disclosed
WO-2006069344-A2 CONTROLLED RELEASE HYDROGELS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2006-06-29 WO disclosed
US-20060121452-A1 Methods for detection of genetic disorders RAVGEN, INC. (US) 2006-06-08 US disclosed
EP-1434791-A4 SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 AMGEN INC (US) 2006-04-26 EP disclosed
EP-1615952-A2 METHODS OF TREATMENT OF INFLAMMATORY DISEASES USING SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 Amgen Inc. (US) 2006-01-18 EP disclosed
WO-2005000902-A1 THE DIMER OF CHIMERIC RECOMBINANT BINDING DOMAIN-FUNCTIONAL GROUP FUSION FORMED VIA DISULFIDE-BOND-BRIDGE AND THE PROCESSES FOR PRODUCING THE SAME CHOE MU-HYEON (KR) 2005-01-06 WO disclosed
WO-2004092215-A2 METHODS OF TREATMENT OF INFLAMMATORY DISEASES USING SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 AMGEN INC. (US) 2004-10-28 WO disclosed
EP-1434791-A2 SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 Amgen, Inc. (US) 2004-07-07 EP disclosed
WO-2003057134-A2 SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 AMGEN, INC. (US) 2003-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320965-A1 PAN-REACTIVE ANTIBODIES TO DUOCARMYCINS GANAB, CNDP2, CD38 MGLL 4080/4885FAAH 3181/4885MAPK1 4033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.